
Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.

SGLT-2 Inhibitors, GLP-1 Receptor Agonists not Cost-effective as First-Line T2D Therapy

Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.

Only 1 lot of each medication was affected by the mislabeling, according to generic repackaging and distribution services company Golden State Medical Supply.

Multimorbidity was associated with a 63% increased risk for dementia among adults older than age 60 years followed for up to 15 years.

Obstructive sleep apnea is a cause of secondary hypertension in up to 50% of cases; more common causes here, from the 2017 ACC/AHA hypertension guidelines.

SGLT-2 inhibitors and drugs to treat HFrEF were compared for efficacy in patients with HF with LVEF ≥40%.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

New survey findings suggest the need for more in-depth conversations with patients about benefits and harms of newer oral therapies for type 2 diabetes.

Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.

Approximately one-third of CV-related ED visits are for hypertension-related conditions, including 13% for essential hypertension among women.

An aspirin deprescribing intervention at anticoagulation clinics led to a 50% reduction in use among patients with AF, VTE prescribed warfarin.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

In patients with type 2 diabetes, for every standard deviation increase in cumulative SBP load there was an increase of at least 10% in CV risk, a new study found.

AHA Hypertension 2022: New research showed that hypertension medication adherence was nearly 76% in large urban areas and increased as population density decreased.

A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.

Physical performance scores used as a proxy for function in adults aged >65 years improved CVD risk prediction beyond traditional risk factors, study authors report.

Artificial sweeteners should not be considered a healthy and safe alternative to sugar, caution French investigators.

Abelacimab is a dual-acting, fully human monoclonal antibody that selectively targets both factor XI and factor XIa with high affinity.

Reducing blood pressure to 140/90 mm Hg or 130/80 mm Hg in high-risk patients proved either cost-saving or cost-effective at 10 years in a simulation study.

AHA Hypertension 2022: Adoption of the DASH diet was found to prevent an estimated 16 000 CVD events among men and 11 000 among women with untreated stage 1 HTN.

AHA Hypertension 2022. Half of patients with newly elevated BP had white coat HTN yet some were diagnosed with HTN at next primary care visit, new study finds.

ESC 2022: SARS-CoV-2 mRNA vaccines were not associated with an increased risk of worsening heart failure, venous thromboembolism, or myocarditis in a large Danish real-world study.

Regardless of where individuals live, they may benefit from blood pressure control programs that increase access to primary health care, study authors suggest.

Find out how effective these 3 and 5 additional ACC/AHA-recommended non-drug interventions are at reducing BP (in mm Hg) in adults with hypertension and with normal BP.

In patients with hypertension, HDL-C >80 mg/dL was linked to a greater risk for CV events among men but not among women. Protective?

Taking a 3-drug polypill (aspirin, ACEi, statin) vs each of the drugs separately reduced risk for a major CV event by 33%, according to results of the SECURE trial.